Henry M. Kuerer, MD, PhD

Henry Kuerer, MD, PhD, FACS, CMQ, on significant advancements in neoadjuvant systemic therapies in breast cancer treatment

Neoadjuvant therapy can eliminate both invasive and in situ carcinoma in up to 50% of patients, particularly when their subtypes are triple-negative disease or HER2-positive cancers.

Henry M. Kuerer, MD, PhD, professor of surgery, The University of Texas MD Anderson Cancer Center, discusses margins of ductal carcinoma in situ (DCIS).

Henry M. Kuerer, MD, PhD, professor of Surgery, The University of Texas MD Anderson Cancer Center, discusses the elimination of breast cancer surgery in exceptional responders.

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses de-escalating surgery in the treatment of patients with breast cancer.

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the challenges associated with treating patients with ductal carcinoma in situ (DCIS).

Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses the overtreatment of DCIS.

Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses sentinel node clipping for post-chemotherapy identification.